文献速递神经与头颈病理

IMP3免疫组化在骨肿瘤中的表达及临床应用的真实世界研究

A real-world study on the expression and clinical application of IMP3 immunohistochemistry in bone tumors.
PubMed 文献 · Hum Pathol · 2025-08-23

该研究对1381例骨肿瘤标本进行IMP3免疫组化检测,分析其在各类骨肿瘤中的差异表达。结果显示IMP3在良性骨肿瘤中阳性率为7.5%(55/732),恶性骨肿瘤为55.2%(358/649),差异有统计学意义(P < 0.0001);高级别恶性肿瘤表达高于低级别。IMP3阳性在弥漫大B细胞淋巴瘤、高级别骨肉瘤、淋巴母细胞淋巴瘤和未分化多形性肉瘤中超过80%;转移性骨癌阳性率为63.5%(80/126),其中肺癌83.6%(46/55)、肝癌70%(7/10)、结直肠癌87.5%(7/8)。IMP3免疫染色可能作为恶性骨肿瘤尤其是骨肉瘤和淋巴瘤的诊断生物标志物。

要点

  • IMP3在恶性骨肿瘤阳性率55.2%,良性7.5%,差异显著(P < 0.0001)。
  • IMP3在弥漫大B细胞淋巴瘤、高级别骨肉瘤等中阳性率超80%。
  • 转移性骨癌中IMP3阳性率63.5%,肺癌、肝癌、结直肠癌转移均高表达。

核心结论

  • IMP3免疫染色可能作为恶性骨肿瘤尤其是骨肉瘤和淋巴瘤的诊断生物标志物。
  • IMP3在肺癌、肝癌和结直肠癌骨转移中高表达,提示其可能与这些恶性肿瘤的骨转移相关。

研究设计与样本

  • 对1381例骨肿瘤标本进行IMP3免疫组化检测,分析不同类型骨肿瘤间的差异表达,并评估其在手术病理中的潜在应用。

主要发现

  • IMP3阳性率在良性骨肿瘤为7.5%(55/732),恶性骨肿瘤为55.2%(358/649),差异有统计学意义(P < 0.0001)。
  • 高级别恶性骨肿瘤IMP3表达水平高于低级别 counterpart。
  • IMP3阳性率在弥漫大B细胞淋巴瘤、高级别骨肉瘤、淋巴母细胞淋巴瘤和未分化多形性肉瘤中超过80%。
  • 转移性骨癌IMP3阳性率为63.5%(80/126),其中肺癌83.6%(46/55)、肝癌70%(7/10)、结直肠癌87.5%(7/8)。
  • 在软骨母细胞瘤、上皮样血管瘤和朗格汉斯细胞组织细胞增生症三种良性骨肿瘤中观察到IMP3高表达。

临床怎么用

  • IMP3免疫组化可作为恶性骨肿瘤(尤其骨肉瘤和淋巴瘤)的辅助诊断标志物。
  • 在骨转移癌鉴别中,IMP3高表达提示可能来源于肺癌、肝癌或结直肠癌。
  • 需注意软骨母细胞瘤、上皮样血管瘤和朗格汉斯细胞组织细胞增生症等良性骨肿瘤也可高表达IMP3,避免误判。

局限性

  • 未来研究应聚焦于阐明IMP3表达与恶性骨肿瘤各种临床病理参数及预后结局的关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previous studies have confirmed that insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) is widely expressed in various malignant tumors. However, no systematic study has assessed the expression of IMP3 in bone tumors. We immunohistochemically examined 1381 bone tumor specimens for IMP3 expression, analyzed its differential expression among various types of bone tumors, and evaluated its potential application in surgical pathology. Our results demonstrated that IMP3 positivity was observed in 7.5 % (55/732) of benign bone tumors and 55.2 % (358/649) of malignant bone tumors, with statistically significant differences (P < 0.0001). Notably, higher levels of IMP3 expression were observed in high-grade malignant bone tumors than in their low-grade counterparts. The incidence of IMP3 positivity exceeds 80 % in diffuse large B-cell lymphoma, high-grade osteosarcoma, lymphoblastic lymphoma, and undifferentiated pleomorphic sarcoma. Additionally, we detected IMP3 positivity in 63.5 % (80/126) of metastatic bone cancers, specifically in 83.6 % (46/55) of lung cancers, 70 % (7/10) of liver cancers, and 87.5 % (7/8) of colorectal cancers. We also observed high levels of IMP3 expression in three benign bone tumor types: chondroblastoma, epithelioid hemangioma, and Langerhans cell histiocytosis. In conclusion, IMP3 immunostaining may serve as a diagnostic biomarker for malignant bone tumors, especially osteosarcoma and lymphoma. The high expression of IMP3 observed in bone metastases of lung cancer, liver cancer, and colorectal cancer indicates that IMP3 could be associated with bone metastasis in these malignancies. Future research should focus on elucidating the relationship between IMP3 expression and various clinicopathological parameters as well as prognostic outcomes in malignant bone tumors.

来源:Hum Pathol,查看原文。版权归原作者所有。

引用

  1. Wei Q, Zhong L, Zhou H, et al. A real-world study on the expression and clinical application of IMP3 immunohistochemistry in bone tumors. Hum Pathol. 2025. PMID: 40854347. doi:10.1016/j.humpath.2025.105911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。